Effects of growth hormone enhanced for parenteral nutrition on immune function and nutrition in elderly patients after esophageal cancer surgery

doi:10.3877/cma.j.issn.1674-0793.2013.05.007

Abstract

Abstract:

Objective

To determine the effects of growth hormone (GH) enriched parenteral nutrition(PN) on nutrition status and immune function in elderly patients after esophageal cancer surgery.

Methods

Seventy-two esophageal cancer patients who underwent the same elective operation were randomized into 2 groups. Both groups were treated with equal calorie and equal nitrogen by central vein during the immediate 10 days after operation. GH enriched PN group was given GH from the 3rd day after operation, and daily dose was 8 U for seven days. The status of immunological parameters and nutrition parameters were observed and analyzed.

Results

Before the operation, the levels of ALB, TF, IgA, IgG, IgM, CD3⁺, CD4⁺, CD4⁺/CD8⁺ of the two groups were less than those of the lower limit of normal value. On the sixth day after operation, all indicators of GH group were better than those of the routine group except of CD8⁺ . On the tenth day, the status of ALB, TF, IgA, IgG, CD4⁺/CD8⁺ of GH group was better than those of the routine group ( P<0.05).

Conclusion

Compared with routine PN, the immune response and nutrition status of elderly patients after esophageal cancer surgery can be ameliorated by GH enhanced PN.

Key words: Growth hormone, Parenteral nutrition, Esophageal cancer

Bin-dong XU, Guo-zhong HUANG, Jin-biao XIE, Jin-shu ZHAO, Hao CHEN, Si-zeng CHEN. Effects of growth hormone enhanced for parenteral nutrition on immune function and nutrition in elderly patients after esophageal cancer surgery[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(05): 358-362.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2013.05.007

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I05/358

Figures/Tables 5

References 22

1	Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med, 2003, 348(2): 138-150.
2	Shaw JH, Koea JB. Metabolic basis for the management of the septic surgical patient. World J Surg, 1993, 17(2): 154-164.
3	Herndon DN, Barrow RE, Kunkel KR, et al. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg, 1990, 212(4): 424- 429.
4	Ziegler TR, Rombeau JL, Young LS, et al. Recombinant human growth hormone enhances the metabolic efficacy of parenteral nutrition: a double-blind, randomized controlled study. J Clin Endocrinol Metab, 1992, 74(4): 865- 873.
5	Xia HH, Zhang ST, Lam SK, et al. Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bileacids and NSAIDs. Carcinogenesis, 2005, 26(1): 11-15.
6	黎介寿. 肿瘤营养学的兴起及临床应用. 肠外与肠内营养, 2004, 11(1): 1-2.
7	Brennan MF, Ekman L. Metabolic consequences of nutritional support of the cancer patient. Cancer, 1984, 54(11 Suppl): 2627-2634.
8	Christensen H, Chemnitz J, Christensen BC, et al. Collagen structural organization of healing colonic anastomoses and the effect of growth hormone treatment. Dis Colon Rectum, 1995, 38(11): 1200-1205.
9	Byrne TA, Morrissey TB, Gatzen C, et al. Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation. Ann Surg, 1993, 218(4): 400-416.
10	Harrison LE, Brennan MF. The role of total parenteral nutrition in the patient with cancer. Curr Probl Surg, 1995, 32(10): 833-917.
11	冉江华，郭群，程家骅, 等. 胃肠道恶性肿瘤患者应用重组人生长激素后免疫功能的变化. 中国普外基础与临床杂志, 1999, 6: 298-300.
12	顾军，黎介寿，李维勤, 等. 重组人生长激素对严重感染后蛋白质代谢影响的实验研究. 中华外科杂志, 1997, 35(2): 104-107.
13	Hammarqvist F, Strömberg C, von der Decken A, et al. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole body nitrogen economy after operation. Ann Surg, 1992, 216(2): 184-191.
14	Kupfer SR, Underwood LE, Baxter RC, et al. Enhancement of the anabolic effects of growth hormone and the insulin-like growth factor by use of both agents simultaneously. J Clin Invest, 1993, 91(2): 391-396.
15	Bettany GE, Camacho-Hubner C, Obeid O, et al. Metabolic effects of adjuvant recombinant human growth hormone in patients with continuing sepsis receiving parenteral nutrition. JPEN J Parenter Enteral Nutr, 1998, 22(4): 199-205.
16	蔡晓敏. 生长激素加营养支持在外科的应用. 肠外与肠内营养, 1999, 6(4): 236-241.
17	李英楠，赵育松，李秀. 类风湿性关节炎外周血T细胞亚群异常及调节的研究. 中国中西医结合杂志, 2002, 22(5): 359-361.
18	Saito H, Inoue T, Fukatsu K, et al. Growth hormone and the immune response to bacterial infection. Horm Res, 1996, 45(1-2): 50-54.
19	Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab, 2006, 91(9): 3494-3498.
20	Fiebig HH, Dengler W, Hendriks HR. No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone. Anticancer Drugs, 2000, 11(8): 659-664.
21	Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab, 2002, 87(7): 3136-3141.
22	Tacke J, Bolder U, Herrmann A, et al. Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone. JPEN J Parenter Enteral Nutr, 2000, 24(3): 140-144.

项目		试验组	对照组	χ²/t值	P值
例数		28	44	?	?
性别（男/女，例）		16/12	30/14	1.98	0.06
年龄（岁，±s）		73.19±9.72	71.37±10.15	0.59	0.66
肿瘤部位（例）		?	?	?	?
?	胸上段	6	5	0.07	0.90
?	胸中段	12	30	1.98	0.06
?	胸下段	10	9	0.40	0.73
手术方式（例）		?	?	?	?
?	颈部吻合	6	18	1.83	0.07
?	弓上吻合	14	16	0.18	0.77
?	弓下吻合	8	10	1.70	0.09

项目		试验组	对照组	χ²/t值	P值
例数		28	44	?	?
性别（男/女，例）		16/12	30/14	1.98	0.06
年龄（岁，±s）		73.19±9.72	71.37±10.15	0.59	0.66
肿瘤部位（例）		?	?	?	?
?	胸上段	6	5	0.07	0.90
?	胸中段	12	30	1.98	0.06
?	胸下段	10	9	0.40	0.73
手术方式（例）		?	?	?	?
?	颈部吻合	6	18	1.83	0.07
?	弓上吻合	14	16	0.18	0.77
?	弓下吻合	8	10	1.70	0.09

组别	例数	血清白蛋白（ALB）			转铁蛋白（TF）
组别	例数	术前1 d	术后第6天	术后第10天	术前1 d	术后第6天	术后第10天
试验组	28	33.86±7.12	31.27±3.99^b	37.88±4.17^a	1.83±0.89	1.66±0.33^b	2.32±0.35^a
对照组	44	32.12±6.53	31.04±4.07^b	33.90±2.89^b	1.79±0.52	1.62±0.56^b	1.85±0.61^b
t值	?	1.77	0.09	2.83	0.30	1.70	2.05
P值	?	0.08	0.81	0.03	0.75	0.09	0.04

组别	例数	血清白蛋白（ALB）			转铁蛋白（TF）
组别	例数	术前1 d	术后第6天	术后第10天	术前1 d	术后第6天	术后第10天
试验组	28	33.86±7.12	31.27±3.99^b	37.88±4.17^a	1.83±0.89	1.66±0.33^b	2.32±0.35^a
对照组	44	32.12±6.53	31.04±4.07^b	33.90±2.89^b	1.79±0.52	1.62±0.56^b	1.85±0.61^b
t值	?	1.77	0.09	2.83	0.30	1.70	2.05
P值	?	0.08	0.81	0.03	0.75	0.09	0.04

组别	例数	IgG			IgA			IgM
组别	例数	术前1天	术后第6天	术后第10天	术前1 d	术后第6天	术后第10天	术前1 d	术后第6天	术后第10天
试验组	28	8.33±1.96	7.61±1.65^b	13.77±1.75^a	1.96±0.87	1.69±0.73^b	3.21±1.78^a	1.91±1.65	1.37±0.76^b	1.73±0.58^b
对照组	44	8.95±3.20	6.50±1.30^b	8.33±1.97^b	1.93±0.51	1.59±0.82^b	2.08±0.33^b	1.88±0.99	1.23±0.69^b	1.65±0.60^b
t值	?	0.43	1.70	3.29	0.07	0.66	2.05	1.77	1.14	1.98
P值	?	0.71	0.09	0.02	0.90	0.63	0.04	0.08	0.24	0.06

Please choose a citation manager

Content to export